Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12662797 | 0.77 | — | — | |
| SCHEMBL9854523 | 0.73 | — | — | |
| SCHEMBL6771973 | 0.72 | MPI (0.40) | MPI | |
| SCHEMBL1745568 | 0.72 | MPI (0.40) | MPI | |
| SCHEMBL24959934 | 0.71 | — | — | |
| SCHEMBL6219720 | 0.70 | AKR1B1 (0.37) | MPI | |
| SCHEMBL3441997 | 0.70 | AKR1B1 (0.37) | MPI | |
| SCHEMBL19480788 | 0.70 | AKR1B1 (0.37) | MPI | |
| Phosphoric Acid SCHEMBL5792557 | 0.70 | MPI (0.48) | MPI | |
| SCHEMBL16600269 | 0.68 | MPI (0.33) | MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055374-A | Lipid compounds and compositions for tissue-specific delivery of active substances | 韩国生命工学研究院 | 2026-05-15 | — | — | CN | claimed |
| CN-121574847-A | Composite microbial agent for flocculating and precipitating cultivation wastewater, biological polysaccharide and application thereof | 黑龙江大学 | 2026-02-27 | — | — | CN | claimed |
| CN-122055374-A | Lipid compounds and compositions for tissue-specific delivery of active substances | 韩国生命工学研究院 | 2026-05-15 | — | — | CN | disclosed |
| US-12569570-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260053912-A1 | STEROLS AS NOVEL IMMUNOMODULATORY AGENTS AND THEIR USE AS VACCINE ADJUVANTS | UNITED STATES GOVERNMENT | 2026-02-26 | — | — | US | disclosed |
| EP-4700124-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Alnylam Pharmaceuticals, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12478671-B2 | Sterols as novel immunomodulatory agents and their use as vaccine adjuvants | OHIO STATE INNOVATION FOUNDATION (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250338808-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | BOYCE THOMPSON INSTITUTE FOR PLANT RES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12382888-B2 | Compositions and methods for modulating immunity in plants | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250236636-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | VERVE THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250236685-A1 | DEGRADABLE POLYMERS | THE TRUSTEES OF BOSTON COLLEGE | 2025-07-24 | — | — | US | disclosed |
| US-20220143189-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-05-12 | — | — | US | disclosed |
| US-20220127605-A1 | NUCLEIC ACID CONJUGATE | KYOWA KIRIN CO., LTD. (JP) | 2022-04-28 | — | — | US | disclosed |
| EP-3019200-B1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | ALNYLAM PHARMACEUTICALS INC (US) | 2022-03-23 | — | — | EP | disclosed |
| WO-2022051677-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | VERVE THERAPEUTICS, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127605-A1 | NUCLEIC ACID CONJUGATE | NSUN3, NSUN2, RNASEH1 | MPI 514/4885 |
| US-20250236636-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | RNGTT, NSUN2, RNMT | MPI 1007/4885 |
| US-12569570-B2 | Compositions and methods for targeted RNA delivery | LDLR, ASGR1, PCSK9 | MPI 3010/4885 |
| US-20220143189-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | HAVCR2, B3GAT3, CSGALNACT1 | MPI 103/4885 |
| US-12478671-B2 | Sterols as novel immunomodulatory agents and their use as vaccine adjuvants | NR1H3, NR1H2, SREBF1 | MPI 1018/4885 |
| US-20250338808-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | SLC11A2, IFNG, STING1 | MPI 749/4885 |
| US-20260053912-A1 | STEROLS AS NOVEL IMMUNOMODULATORY AGENTS AND THEIR USE AS VACCINE ADJUVANTS | HLA-DRB1, NFATC1, CD4 | MPI 2743/4885 |
| US-12382888-B2 | Compositions and methods for modulating immunity in plants | SLC11A2, IFNG, STING1 | MPI 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.